Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer's disease: The Hisayama study

Kouhei Fujimi, Kazuhito Noda, Kensuke Sasaki, Yoshinobu Wakisaka, Yumihiro Tanizaki, Mitsuo Iida, Yutaka Kiyohara, Shigenobu Kanba, Toru Iwaki

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: It has been reported that nonsteroidal anti-inflammatory drugs may delay the onset of Alzheimer's disease (AD). Since nonsteroidal anti-inflammatory drugs inhibit cyclooxygenase (COX), COX-2, an inducible form of COX, may be involved in the pathology of AD in association with the arachidonic acid cascade. In addition, it has been suggested that alterations in the balance of polyunsaturated fatty acids are associated with brain dysfunctions such as neurodegerative pathologies of the aging brain. Method: To explore COX-2 expression in the hippocampus, we analyzed 45 consecutive autopsy subjects without dementia and 25 AD patients derived from the town of Hisayama, Japan. Results: The neuronal expression of COX-2 in the CA3 subdivision of the hippocampus, subiculum, entorhinal cortex and transentorhinal cortex were consistently observed in both nondemented and AD brains, and COX-2 immunoreactivity correlated with age in nondemented brains. In AD patients, neurons of CA1 exhibited increased COX-2 immunoreactivity which correlated with the severity of AD pathology. This correlation was not apparent in nondemented subjects. Conclusion: These results suggest that COX-2 expression may be differentially regulated among subdivisions of the hippocampus and that elevated COX-2 expression in the CA1 of AD brains may be associated with AD pathology and thus cognitive dysfunction.

Original languageEnglish
Pages (from-to)423-431
Number of pages9
JournalDementia and Geriatric Cognitive Disorders
Volume23
Issue number6
DOIs
Publication statusPublished - May 1 2007

Fingerprint

Cyclooxygenase 2
Hippocampus
Alzheimer Disease
Pathology
Brain
Prostaglandin-Endoperoxide Synthases
Anti-Inflammatory Agents
Entorhinal Cortex
Unsaturated Fatty Acids
Arachidonic Acid
Pharmaceutical Preparations
Dementia
Autopsy
Japan
Neurons

All Science Journal Classification (ASJC) codes

  • Geriatrics and Gerontology
  • Cognitive Neuroscience
  • Psychiatry and Mental health

Cite this

Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer's disease : The Hisayama study. / Fujimi, Kouhei; Noda, Kazuhito; Sasaki, Kensuke; Wakisaka, Yoshinobu; Tanizaki, Yumihiro; Iida, Mitsuo; Kiyohara, Yutaka; Kanba, Shigenobu; Iwaki, Toru.

In: Dementia and Geriatric Cognitive Disorders, Vol. 23, No. 6, 01.05.2007, p. 423-431.

Research output: Contribution to journalArticle

Fujimi, Kouhei ; Noda, Kazuhito ; Sasaki, Kensuke ; Wakisaka, Yoshinobu ; Tanizaki, Yumihiro ; Iida, Mitsuo ; Kiyohara, Yutaka ; Kanba, Shigenobu ; Iwaki, Toru. / Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer's disease : The Hisayama study. In: Dementia and Geriatric Cognitive Disorders. 2007 ; Vol. 23, No. 6. pp. 423-431.
@article{2354017f38fc41218818d5dc316c918c,
title = "Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer's disease: The Hisayama study",
abstract = "Background: It has been reported that nonsteroidal anti-inflammatory drugs may delay the onset of Alzheimer's disease (AD). Since nonsteroidal anti-inflammatory drugs inhibit cyclooxygenase (COX), COX-2, an inducible form of COX, may be involved in the pathology of AD in association with the arachidonic acid cascade. In addition, it has been suggested that alterations in the balance of polyunsaturated fatty acids are associated with brain dysfunctions such as neurodegerative pathologies of the aging brain. Method: To explore COX-2 expression in the hippocampus, we analyzed 45 consecutive autopsy subjects without dementia and 25 AD patients derived from the town of Hisayama, Japan. Results: The neuronal expression of COX-2 in the CA3 subdivision of the hippocampus, subiculum, entorhinal cortex and transentorhinal cortex were consistently observed in both nondemented and AD brains, and COX-2 immunoreactivity correlated with age in nondemented brains. In AD patients, neurons of CA1 exhibited increased COX-2 immunoreactivity which correlated with the severity of AD pathology. This correlation was not apparent in nondemented subjects. Conclusion: These results suggest that COX-2 expression may be differentially regulated among subdivisions of the hippocampus and that elevated COX-2 expression in the CA1 of AD brains may be associated with AD pathology and thus cognitive dysfunction.",
author = "Kouhei Fujimi and Kazuhito Noda and Kensuke Sasaki and Yoshinobu Wakisaka and Yumihiro Tanizaki and Mitsuo Iida and Yutaka Kiyohara and Shigenobu Kanba and Toru Iwaki",
year = "2007",
month = "5",
day = "1",
doi = "10.1159/000101957",
language = "English",
volume = "23",
pages = "423--431",
journal = "Dementia and Geriatric Cognitive Disorders",
issn = "1420-8008",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer's disease

T2 - The Hisayama study

AU - Fujimi, Kouhei

AU - Noda, Kazuhito

AU - Sasaki, Kensuke

AU - Wakisaka, Yoshinobu

AU - Tanizaki, Yumihiro

AU - Iida, Mitsuo

AU - Kiyohara, Yutaka

AU - Kanba, Shigenobu

AU - Iwaki, Toru

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Background: It has been reported that nonsteroidal anti-inflammatory drugs may delay the onset of Alzheimer's disease (AD). Since nonsteroidal anti-inflammatory drugs inhibit cyclooxygenase (COX), COX-2, an inducible form of COX, may be involved in the pathology of AD in association with the arachidonic acid cascade. In addition, it has been suggested that alterations in the balance of polyunsaturated fatty acids are associated with brain dysfunctions such as neurodegerative pathologies of the aging brain. Method: To explore COX-2 expression in the hippocampus, we analyzed 45 consecutive autopsy subjects without dementia and 25 AD patients derived from the town of Hisayama, Japan. Results: The neuronal expression of COX-2 in the CA3 subdivision of the hippocampus, subiculum, entorhinal cortex and transentorhinal cortex were consistently observed in both nondemented and AD brains, and COX-2 immunoreactivity correlated with age in nondemented brains. In AD patients, neurons of CA1 exhibited increased COX-2 immunoreactivity which correlated with the severity of AD pathology. This correlation was not apparent in nondemented subjects. Conclusion: These results suggest that COX-2 expression may be differentially regulated among subdivisions of the hippocampus and that elevated COX-2 expression in the CA1 of AD brains may be associated with AD pathology and thus cognitive dysfunction.

AB - Background: It has been reported that nonsteroidal anti-inflammatory drugs may delay the onset of Alzheimer's disease (AD). Since nonsteroidal anti-inflammatory drugs inhibit cyclooxygenase (COX), COX-2, an inducible form of COX, may be involved in the pathology of AD in association with the arachidonic acid cascade. In addition, it has been suggested that alterations in the balance of polyunsaturated fatty acids are associated with brain dysfunctions such as neurodegerative pathologies of the aging brain. Method: To explore COX-2 expression in the hippocampus, we analyzed 45 consecutive autopsy subjects without dementia and 25 AD patients derived from the town of Hisayama, Japan. Results: The neuronal expression of COX-2 in the CA3 subdivision of the hippocampus, subiculum, entorhinal cortex and transentorhinal cortex were consistently observed in both nondemented and AD brains, and COX-2 immunoreactivity correlated with age in nondemented brains. In AD patients, neurons of CA1 exhibited increased COX-2 immunoreactivity which correlated with the severity of AD pathology. This correlation was not apparent in nondemented subjects. Conclusion: These results suggest that COX-2 expression may be differentially regulated among subdivisions of the hippocampus and that elevated COX-2 expression in the CA1 of AD brains may be associated with AD pathology and thus cognitive dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=34250221511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250221511&partnerID=8YFLogxK

U2 - 10.1159/000101957

DO - 10.1159/000101957

M3 - Article

C2 - 17457030

AN - SCOPUS:34250221511

VL - 23

SP - 423

EP - 431

JO - Dementia and Geriatric Cognitive Disorders

JF - Dementia and Geriatric Cognitive Disorders

SN - 1420-8008

IS - 6

ER -